A Study to Evaluate Whether Natalizumab Modifies the Changes in Melatonin and Oxidative Stress Biomarkers in Patients With Relapsing-Remitting Multiple Sclerosis
Latest Information Update: 22 Feb 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
Most Recent Events
- 22 Feb 2016 New trial record